WallStreetZenWallStreetZen

NASDAQ: RDHL
Redhill Biopharma Ltd Stock

$0.39-0.01 (-2.5%)
Updated Jun 14, 2024
RDHL Price
$0.39
Fair Value Price
N/A
Market Cap
$14.88M
52 Week Low
$0.26
52 Week High
$3.28
P/E
0.1x
P/B
7.19x
P/S
0.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.53M
Earnings
$23.92M
Gross Margin
47%
Operating Margin
193.45%
Profit Margin
366.2%
Debt to Equity
10.14
Operating Cash Flow
-$36M
Beta
0.98
Next Earnings
Aug 15, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RDHL Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RDHL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RDHL is good value based on its earnings relative to its share price (0.1x), compared to the US market average (30.51x)
P/E vs Market Valuation
RDHL is good value based on its earnings relative to its share price (0.1x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.12x)
P/E vs Industry Valuation
RDHL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more RDHL due diligence checks available for Premium users.

Be the first to know about important RDHL news, forecast changes, insider trades & much more!

RDHL News

Valuation

RDHL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0.1x
Industry
2.12x
Market
30.51x
RDHL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RDHL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

RDHL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
7.19x
Industry
2.14x
RDHL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RDHL's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
RDHL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RDHL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$23.0M
Liabilities
$21.0M
Debt to equity
10.14
RDHL's short-term liabilities ($19.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RDHL's short-term assets ($16.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RDHL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RDHL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
RDHL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RDHL vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
RDHL$14.88M-2.75%0.10x7.19x
FLGC$14.10M-2.65%-0.14x4.49x
AYTU$15.87M-0.70%-1.17x0.52x
KALA$16.79M-0.67%-0.40x2.52x
GHSI$12.95M-0.15%-2.51x3.79x

Redhill Biopharma Stock FAQ

What is Redhill Biopharma's quote symbol?

(NASDAQ: RDHL) Redhill Biopharma trades on the NASDAQ under the ticker symbol RDHL. Redhill Biopharma stock quotes can also be displayed as NASDAQ: RDHL.

If you're new to stock investing, here's how to buy Redhill Biopharma stock.

What is the 52 week high and low for Redhill Biopharma (NASDAQ: RDHL)?

(NASDAQ: RDHL) Redhill Biopharma's 52-week high was $3.28, and its 52-week low was $0.26. It is currently -88.14% from its 52-week high and 51.36% from its 52-week low.

How much is Redhill Biopharma stock worth today?

(NASDAQ: RDHL) Redhill Biopharma currently has 12,746,797,800 outstanding shares. With Redhill Biopharma stock trading at $0.39 per share, the total value of Redhill Biopharma stock (market capitalization) is $14.88M.

Redhill Biopharma stock was originally listed at a price of $444.00 in Jan 7, 2013. If you had invested in Redhill Biopharma stock at $444.00, your return over the last 11 years would have been -99.91%, for an annualized return of -47.27% (not including any dividends or dividend reinvestments).

How much is Redhill Biopharma's stock price per share?

(NASDAQ: RDHL) Redhill Biopharma stock price per share is $0.39 today (as of Jun 14, 2024).

What is Redhill Biopharma's Market Cap?

(NASDAQ: RDHL) Redhill Biopharma's market cap is $14.88M, as of Jun 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Redhill Biopharma's market cap is calculated by multiplying RDHL's current stock price of $0.39 by RDHL's total outstanding shares of 12,746,797,800.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.